The clarification from the German biotech company comes on the heels of a Bloomberg report that Pfizer is considering selling ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

The "USA Vaccine Market outlook to 2030" report has been added to ResearchAndMarkets.com's offering. The USA vaccine market is valued at approximately USD 30 billion, based on recent market ...

SAN FRANCISCO -- One of the front-runners in the quest for a COVID-19 vaccine is reporting hopeful news. Pfizer says its vaccine is proving to be safe during phase three trials. RELATED: Oxford, ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Pfizer CEO Albert Bourla said people will "likely" need a booster dose of a COVID-19 vaccine within 12 months of getting fully vaccinated. His comments were made public Thursday but were taped April 1 ...